



## **Endologix Files Motion to Discontinue Court Proceedings Related to Alleged Patent Infringement**

IRVINE, Calif., Nov 24, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- Endologix, Inc. (Nasdaq: ELGX), developer of minimally invasive treatments for aortic disorders, announced today that it has filed a motion to stay, or discontinue all proceedings in, the patent infringement lawsuit brought against it in October 2009 by Cook, Inc. The motion was filed in the United States District Court in Indianapolis, Indiana.

Endologix has requested that the stay remain in effect while the United States Patent and Trademark Office (USPTO) conducts proceedings to re-examine the two patents asserted by Cook in the lawsuit and determine whether it should have granted Cook the patents. Endologix has already filed papers requesting that the USPTO re-examine the two Cook patents, based on patents that pre-date Cook's patents and were not previously considered by the USPTO in its decision to grant the patents to Cook.

John McDermott, Endologix President and Chief Executive Officer, said, "In addition to contesting the validity of Cook's patents, we also intend to challenge the lawsuit on other grounds, including non-infringement of the Cook patents by our products. We continue to believe we have support for numerous promising defenses against this infringement case."

### *About Endologix, Inc.*

Endologix, Inc. develops and manufactures minimally invasive treatments for aortic disorders. The Company's flagship product is the Powerlink(R) System, which is an endovascular stent graft for the treatment of abdominal aortic aneurysms (AAA). AAA is a weakening of the wall of the aorta, the largest artery in the body, resulting in a balloon-like enlargement. Once AAA develops, it continues to enlarge and, if left untreated, becomes increasingly susceptible to rupture. Additional information can be found on Endologix's Web site at [www.endologix.com](http://www.endologix.com)

### *Forward-Looking Statements*

*Except for historical information contained herein, this news release contains forward-looking statements, specifically related to the claims of alleged infringement. Please refer to the Company's Annual Report on Form 10-K for the year ended December 31, 2008, and the Company's other filings with the Securities and Exchange Commission, for more detailed information regarding these risks and other factors that may cause actual results to differ materially from those expressed or implied.*

COMPANY CONTACT:  
Endologix, Inc.  
John McDermott, CEO  
(949) 595-7200  
[www.endologix.com](http://www.endologix.com)

INVESTOR CONTACTS:  
The Ruth Group  
Nick Laudico (646) 536-7030  
Zack Kubow (646) 536-7020

SOURCE Endologix, Inc.

<http://www.endologix.com>

Copyright (C) 2009 PR Newswire. All rights reserved